Cytiva: AI Drug Discovery Outpaces Manufacturing
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cytiva says AI and big data are flooding drug discovery pipelines with high-potential drug candidates, outstripping the technology to mass-manufacture them safely for the global public.
- Scaling drug production from lab flasks to commercial bioreactors introduces non-linear biological and engineering shifts that can undermine purification tasks, the company warns.
- Henrik Ihre (Distinguished Fellow, Cytiva) and Paul Belcher (Business Leader, Cytiva) appear on the New Scientist CoLab podcast to discuss the high-stakes science of drug purification.
- The episode addresses the human cost when purification goes wrong and the challenge of keeping manufacturing pace as AI supercharges drug discovery.
- Chapter topics include chromatography resin (23:20), why purification becomes more difficult later in the process (25:24), and whether AI is currently helping with purification (37:52).
Why it matters: Cytiva flags that the bottleneck is shifting from discovery to manufacturing — particularly purification — meaning promising AI-generated drug candidates risk stalling or failing in scale-up even after the science succeeds, potentially delaying patient access.
Ask SkimNews
